Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.

U.S. stock futures and global equities markets tumbled along with the dollar and Treasury yields following the Trump ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

Key Insights The considerable ownership by individual investors in Novartis indicates that they collectively have ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.

Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...

Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...